Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to -$75.8 million.

  • Ani Pharmaceuticals' Net Cash Flow rose 146.56% to $44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.9 million, marking a year-over-year increase of 343.62%. This contributed to the annual value of -$75.8 million for FY2024, which is 145.12% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Net Cash Flow stood at -$75.8 million for FY2024, which was down 145.12% from $167.9 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Net Cash Flow ranged from a high of $167.9 million in FY2023 and a low of -$75.8 million during FY2024.
  • For the 3-year period, Ani Pharmaceuticals' Net Cash Flow averaged around $13.4 million, with its median value being -$52.1 million (2022).
  • In the last 5 years, Ani Pharmaceuticals' Net Cash Flow slumped by 381.88% in 2020 and then soared by 422.44% in 2023.
  • Ani Pharmaceuticals' Net Cash Flow (Yearly) stood at -$54.5 million in 2020, then spiked by 269.62% to $92.4 million in 2021, then tumbled by 156.33% to -$52.1 million in 2022, then soared by 422.44% to $167.9 million in 2023, then tumbled by 145.12% to -$75.8 million in 2024.